A Comparative Study on the Level of Hepatic Steatosis and Fibrosis between Pre- and Post-Intravenous Chelation Therapy in Patients with Chronic Lead Poisoning.

Not Applicable

Recruiting

• Conditions: Chronic lead poisoningHepatic steatosisHepatic fibrosis; Chronic lead poisoning; Hepatotoxicity; Hepatic steatosis; Hepatic fibrosis; Hepatitis; Interleukin- 1; Glutathione

• Registration Number: TCTR20180904002
• Lead Sponsor: Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-09-04
• Study Completion: 2018-12-03
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Blood lead level equal to or above 70 mcg/dl
Occupational lead exposure for more than 1 year

Exclusion Criteria

Viral hepatitis B or C
Autoimmune hepatitis
Wilson disease
Hemochromatosis
Significant alcohol consumption
Diabetes
Triglyceride level >200 mg/dL
Waist circumference > 102 cm in men and > 88 cm in women
Symptoms of acute lead poisoning
Prior lead chelation therapy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hepatic steatosis Before and after intravenously lead chelation CAP (Fibroscan),Hepatic fibrosis Before and after intravenously lead chelation Fibroscan

Secondary Outcome Measures

Name	Time	Method
iver function test Before and after intravenously lead chelation Blood chemistry test,Inflammatory mediators/ biomarkers Before and after intravenously lead chelation Blood test